PlainPharmaWatch

CMS Open Payments · Program Year 2024

Neocis Inc.

Neocis Inc. reported $209,571.71 across General Payments, Research, and Ownership to 76 physicians and teaching hospitals across 76 transactions.

$209.6K
All-tracks total
76
Transactions
76
Recipients
+$67.5K
General Payments vs PY2023

Neocis Inc. reported $209,571.71 across all CMS Open Payments tracks (General + Research + Ownership) to 76 physicians and teaching hospitals in Program Year 2024 - ranking #986 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $209,571.71, averaging $2.8K per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer neocis-inc Neocis Inc.

$209.6K · #986/1,925 · 0.0% industry · PY2024

  • TOT $209.6K
  • RANK #986
  • SHARE 0.0%
  • TXN 76
  • RCP 76
  • CAT 3
  • GEN $209.6K
  • ΔGEN +$67.5K
  • TOP1 21.3%
  • PY 2024

Nearest volume peer: Cardinal Health 200 LLC ($209.6K)

Surgical Specialties Corpora…$210.1KCardinal Health 200 LLC$209.6KNeocis Inc. (this)$209.6KMindray DS USA, Inc.$209.1KDiagnostica Stago, Inc$208.5K
All-tracks payment totals near Neocis Inc. (CMS Open Payments PY2024)

Neocis Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Neocis Inc.'s CMS-reported General Payments increased by $67.5K (+47.5%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: NEOCIS INC.PY2023: NEOCIS INC.PY2024: Neocis Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$142.1KPY2024$209.6K
PY2023
$142,084.75
PY2024
$209,571.71

What the Data Shows for Neocis Inc.

Neocis Inc. ranks #986 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $209,571.71 across 76 transactions to 76 physicians and teaching hospitals - $2.8K per transaction and $2.8K per recipient on average.

Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $205.0K across 73 transactions, 97.8% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

Neocis Inc. made 3 types of general payments. "Consulting Fee" is the largest category at $205.0K, 97.8% of General Payments.

How Neocis Inc. divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$205.0K2. Compensation for Services…$4.0K3. Food and Beverage$537.95
Payment Type Amount Transactions
Consulting Fee $205.0K 73
Compensation for Services Other Than Consulting $4.0K 1
Food and Beverage $537.95 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $130,127.62 (62.1%) of $209,571.71 in this company's General Payments records across 24 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Neocis Inc.

The five named recipients with the highest reported General Payments from this company

Leo Haydt$44.6KScott Ewing$30.5KJeremy Thompson$20.3KSathish Gobichettypalayam$20.3KHanife Bayraktaroglu$14.4K
  1. 1

    Leo Haydt

    $44,604.67 across 7 reported transactions

  2. 2

    Scott Ewing

    $30,542.71 across 5 reported transactions

  3. 3

    Jeremy Thompson

    $20,313.87 across 19 reported transactions

  4. 4

    Sathish Gobichettypalayam

    $20,266.37 across 6 reported transactions

  5. 5

    Hanife Bayraktaroglu

    $14,400.00 across 3 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Neocis Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Neocis Inc..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Neocis Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Neocis Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.